|Mr. Jay P. Shepard||Pres, CEO & Director||818.29k||N/A||1958|
|Mr. Vinay Shah||Chief Financial Officer||112.01k||N/A||1962|
|Dr. Jeffrey L. Cleland||Co-Founder||N/A||N/A||1965|
|Dr. Joshua Silverman Ph.D.||Co-Founder||N/A||N/A||N/A|
|Dr. Gail F. McIntyre||Chief Scientific Officer||N/A||N/A||1963|
Aravive, Inc., a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. Its lead candidate is AVB-S6-500, a soluble Fc-fusion protein, which is in Phase 1b/2 clinical trials for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer, and pancreatic cancer. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.
Aravive, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.